# CASIF (Casi Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Casi Pharmaceuticals, Inc. reported $20.71M in revenue and a net loss of $48.06M for the fiscal year ended December 31, 2025 (down 27.4% year over year), with a 48.6% gross margin and a -217.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/CASIF
- Markdown: https://convexityos.com/fundamentals/CASIF.md
- SEC CIK: 0001962738
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 21, 2026, 05:12 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001962738&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $20.71M | -27.4% YoY |
| Operating Income | FY 2025 | -$45.01M | -217.3% margin |
| Net Income | FY 2025 | -$48.06M | -232.0% net margin |
| Diluted EPS | FY 2025 | -$2.59 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$20.77M | -100.3% FCF margin |
| Cash & ST Investments | Dec 31, 2025 | $5.63M | Total debt: $22.24M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $20.71M | $28.54M | $33.88M | $43.11M | $30.17M | $15.14M |
| Cost of Revenue | $10.64M | $17.39M | $13.83M | $15.83M | $12.56M | $9.51M |
| **Gross Profit** | $10.08M | $11.15M | $20.05M | $27.28M | $17.61M | $5.63M |
| Research & Development | $6.31M | $8.92M | $9.86M | $16.00M | $14.42M | $11.47M |
| Selling, General & Admin | $46.61M | $41.44M | $41.84M | $37.77M | $38.41M | $27.48M |
| **Operating Income** | -$45.01M | -$39.62M | -$25.08M | -$34.03M | -$41.52M | -$52.78M |
| **EBITDA** | -$43.81M | -$38.32M | -$22.58M | -$32.83M | -$41.02M | -$52.18M |
| Interest Expense | -- | -- | -- | $0 | $2.9K | $3.1K |
| Income Before Tax | -$45.87M | -$38.07M | -$26.29M | -$37.43M | -$35.84M | -$47.51M |
| Income Tax Expense | -- | $0 | -$81K | $1.98M | $0 | $0 |
| **Net Income** | -$48.06M | -$39.26M | -$26.96M | -$41.01M | -$36.65M | -$48.29M |
| Basic EPS | -$2.59 | -$2.56 | -$2.02 | -$3.01 | -$2.69 | -$4.37 |
| **Diluted EPS** | -$2.59 | -$2.56 | -$2.02 | -$3.01 | -$2.69 | -$4.37 |
| Basic Shares Outstanding | 18.5M | 15.3M | 13.4M | 13.6M | 13.6M | 11.0M |
| Diluted Shares Outstanding | 18.5M | 15.3M | 13.4M | 13.6M | 13.6M | 11.0M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $5.63M | $13.47M | $17.08M | $47.11M | $38.70M |
| Short-Term Investments | -- | -- | $12.01M | $1.46M | $9.87M |
| **Cash & Short-Term Investments** | $5.63M | $13.47M | $29.09M | $48.57M | $48.57M |
| Accounts Receivable, Net | $4.09M | $15.35M | $9.55M | $12.97M | $9.80M |
| Inventory | $1.60M | $5.25M | $15.88M | $6.14M | $1.91M |
| **Total Current Assets** | $13.46M | $39.58M | $59.34M | $73.42M | $61.97M |
| Property, Plant & Equipment, Net | $6.97M | $7.87M | $9.24M | $11.83M | $12.71M |
| Intangible Assets | $221K | $238K | $1.84M | $1.06M | $12.20M |
| Long-Term Investments | $1.72M | $1.91M | $1.69M | $4.40M | $40.13M |
| Other Non-Current Assets | $740K | $587K | $766K | $1.06M | $2.18M |
| **Total Non-Current Assets** | $12.19M | $14.10M | $15.92M | $22.81M | $76.33M |
| **Total Assets** | $25.65M | $53.67M | $75.27M | $96.23M | $138.3M |
| Accounts Payable | $1.06M | $2.72M | $4.44M | $3.29M | $2.22M |
| Short-Term Debt | $19.19M | $18.39M | -- | -- | -- |
| Other Current Liabilities | $2.23M | $1.33M | $1.12M | $648K | $519K |
| **Total Current Liabilities** | $49.67M | $36.45M | $16.73M | $17.00M | $13.19M |
| Long-Term Debt | -- | -- | $18.89M | -- | -- |
| Other Non-Current Liabilities | $13.26M | $15.37M | $15.48M | $12.30M | $14.32M |
| **Total Non-Current Liabilities** | $13.26M | $15.37M | $34.38M | $12.30M | $17.15M |
| **Total Liabilities** | $62.93M | $51.82M | $51.10M | $29.30M | $30.34M |
| **Total Debt (incl. Leases)** | $22.24M | $22.14M | $21.24M | $1.34M | $2.17M |
| Common Stock | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$748.1M | -$700.1M | -$660.8M | -$637.2M | -$605.6M |
| Accumulated Other Comp. Income | -$1.78M | -$1.77M | -$1.20M | -$703K | $1.95M |
| **Total Stockholders' Equity** | -$37.28M | $1.85M | $24.16M | $44.57M | $84.50M |
| Total Equity | -$37.28M | $1.85M | $24.16M | $44.57M | $84.50M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $5.63M | $13.47M | $17.08M | $47.11M | $38.70M |
| Short-Term Investments | -- | -- | $12.01M | $1.46M | $9.87M |
| **Cash & Short-Term Investments** | $5.63M | $13.47M | $29.09M | $48.57M | $48.57M |
| Accounts Receivable, Net | $4.09M | $15.35M | $9.55M | $12.97M | $9.80M |
| Inventory | $1.60M | $5.25M | $15.88M | $6.14M | $1.91M |
| **Total Current Assets** | $13.46M | $39.58M | $59.34M | $73.42M | $61.97M |
| Property, Plant & Equipment, Net | $6.97M | $7.87M | $9.24M | $11.83M | $12.71M |
| Intangible Assets | $221K | $238K | $1.84M | $1.06M | $12.20M |
| Long-Term Investments | $1.72M | $1.91M | $1.69M | $4.40M | $40.13M |
| Other Non-Current Assets | $740K | $587K | $766K | $1.06M | $2.18M |
| **Total Non-Current Assets** | $12.19M | $14.10M | $15.92M | $22.81M | $76.33M |
| **Total Assets** | $25.65M | $53.67M | $75.27M | $96.23M | $138.3M |
| Accounts Payable | $1.06M | $2.72M | $4.44M | $3.29M | $2.22M |
| Short-Term Debt | $19.19M | $18.39M | -- | -- | -- |
| Other Current Liabilities | $2.23M | $1.33M | $1.12M | $648K | $519K |
| **Total Current Liabilities** | $49.67M | $36.45M | $16.73M | $17.00M | $13.19M |
| Long-Term Debt | -- | -- | $18.89M | -- | -- |
| Other Non-Current Liabilities | $13.26M | $15.37M | $15.48M | $12.30M | $14.32M |
| **Total Non-Current Liabilities** | $13.26M | $15.37M | $34.38M | $12.30M | $17.15M |
| **Total Liabilities** | $62.93M | $51.82M | $51.10M | $29.30M | $30.34M |
| **Total Debt (incl. Leases)** | $22.24M | $22.14M | $21.24M | $1.34M | $2.17M |
| Common Stock | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$748.1M | -$700.1M | -$660.8M | -$637.2M | -$605.6M |
| Accumulated Other Comp. Income | -$1.78M | -$1.77M | -$1.20M | -$703K | $1.95M |
| **Total Stockholders' Equity** | -$37.28M | $1.85M | $24.16M | $44.57M | $84.50M |
| Total Equity | -$37.28M | $1.85M | $24.16M | $44.57M | $84.50M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$48.06M | -$39.26M | -$26.26M | -$40.26M | -$35.84M | -$47.51M |
| Depreciation & Amortization | $1.20M | $1.30M | $2.50M | $1.20M | $500K | $600K |
| Stock-Based Compensation | $2.99M | $1.31M | $7.22M | $7.01M | $7.77M | $7.82M |
| Change in Receivables | $11.25M | -$5.79M | $3.42M | -$3.17M | -$5.16M | -$3.35M |
| Change in Inventory | $2.50M | $5.83M | -$9.74M | -$4.23M | -$551K | $3.19M |
| Change in Payables | -$1.66M | -$1.72M | $1.15M | $1.07M | $1.49M | -$1.54M |
| **Operating Cash Flow** | -$20.75M | -$29.22M | -$19.97M | -$21.09M | -$26.84M | -$25.89M |
| Capital Expenditure | -$16K | -$223K | -$204K | -$5.61M | -$8.95M | -$1.50M |
| **Free Cash Flow** | -$20.77M | -$29.45M | -$20.17M | -$26.70M | -$35.79M | -$27.39M |
| **Investing Cash Flow** | $951K | $11.24M | -$9.67M | $31.16M | -$20.69M | -$20.72M |
| Share Repurchases | -- | -- | -$278K | -$3.27M | -- | -- |
| **Financing Cash Flow** | $11.25M | $15.43M | -$907K | -$3.27M | $29.64M | $47.15M |
| **Net Change in Cash** | -$7.84M | -$3.62M | -$30.03M | $8.41M | -$18.36M | $3.44M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 48.6% | 39.1% | 59.2% | 63.3% | 58.4% | 37.2% |
| **Operating Margin** | -217.3% | -138.8% | -74.0% | -78.9% | -137.6% | -348.6% |
| **Net Profit Margin** | -232.0% | -137.6% | -79.6% | -95.1% | -121.5% | -318.9% |
| Return on Equity (ROE) | -- | -2120.9% | -111.6% | -92.0% | -43.4% | -- |
| Return on Assets (ROA) | -187.4% | -73.1% | -35.8% | -42.6% | -26.5% | -- |
| Current Ratio | 0.27x | 1.09x | 3.55x | 4.32x | 4.70x | -- |
| Quick Ratio | 0.24x | 0.94x | 2.60x | 3.96x | 4.56x | -- |
| Debt to Equity | -- | 11.96x | 0.88x | 0.03x | 0.03x | -- |
| **Revenue Growth (YoY)** | -27.4% | -15.8% | -21.4% | +42.9% | +99.2% | -- |
| Gross Profit Growth (YoY) | -9.6% | -44.4% | -26.5% | +54.9% | +212.6% | -- |
| 5Y Revenue / Share Growth | -18.5% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
